Brief: Xencor Reports Initial Dose-Escalation Data From Phase 1 Study Of Xmab®104, Pd-1 X Icos Bispecific Antibody, In Advanced Solid Tumors
27/05/2022 24:51
May 26 (Reuters) - Xencor Inc XNCR.O :
* XENCOR REPORTS INITIAL DOSE-ESCALATION DATA FROM PHASE 1
STUDY
OF XMAB®104, PD-1 X ICOS BISPECIFIC ANTIBODY, IN ADVANCED SOLID
TUMORS
Source text for Eikon: ID:nBwxbB5La
Further company coverage: XNCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xencor
See all newsXencor, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates